Previous studies have indicated that excitatory amino acids are involv
ed in the analgesic and addictive properties of morphine. However, the
ir role in the morphine-induced alterations in glucose metabolism is n
ot known. This study assessed the contribution of NMDA receptor activa
tion to the morphine-induced hormonal and metabolic alterations in con
scious unrestrained chronically catheterized rats. Whole body glucose
flux was assessed with a primed constant intravenous infusion of [3-H-
3]glucose in rats pretreated with the NMDA-receptor antagonist MK-801
(0.25 mg/kg, intraarterial) or an equal volume (1.5 ml) of sterile sal
ine (0.9%) administered 15 min prior to i.c.v. injection of H2O (Con;
5 mu l) or morphine sulfate (80 mu g). No significant alterations were
noted in metabolic and hormonal parameters of H2O injected rats. i.c.
v. morphine increased the plasma glucose concentration (60%), hepatic
glucose production (R(a); 60%) and whole body glucose utilization (R(d
); 53%), but did not alter the glucose metabolic clearance rate (MCR).
MK-801 alone resulted in transient hyperglycemia (25%), stimulation o
f glucose R(a) (60%) and glucose R(d) (53%), and a significant (30%) i
ncrease in MCR. MK-801 pretreatment blunted the morphine-induced hyper
glycemia and the increased glucose R(a) and R(d). Morphine increased t
he plasma concentration of epinephrine (4-fold), norepinephrine (2-fol
d) and corticosterone (67%); however, no alterations in plasma insulin
and glucagon were detected. MK-801 pretreatment, blunted the morphine
-induced increase in corticosterone and norepinephrine, and elicited a
significant rise in insulin concentrations. These results indicate th
at activation of the NMDA receptors contributes to the morphine-induce
d hyperglycemia and hormonal alterations. Furthermore, this response a
ppears partially mediated by activation of sympathetic outflow and sup
pression of insulin release, which is blunted by inhibition of NMDA re
ceptors.